ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,825
0,27%
Bitcoin
93 533,64
0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mangoceuticals Inc (MGRX)

  7. Mangoceuticals Inc (MGRX) Actualités

MGRX

Mangoceuticals (MGRX)

Mangoceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MGRX
DateHeureSourceTitreSymboleSociété
26/12/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
19/12/202423h33GlobeNewswire Inc.Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations PatentNASDAQ:MGRXMangoceuticals Inc
04/12/202413h00GlobeNewswire Inc.Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock SplitNASDAQ:MGRXMangoceuticals Inc
14/11/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MGRXMangoceuticals Inc
31/10/202413h00GlobeNewswire Inc.Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:MGRXMangoceuticals Inc
22/10/202414h00GlobeNewswire Inc.MangoRx Announces Formation of Strategy and Alternatives CommitteeNASDAQ:MGRXMangoceuticals Inc
21/10/202423h10GlobeNewswire Inc.MangoRx Responds to and Refutes Recent Claims Made by Eli LillyNASDAQ:MGRXMangoceuticals Inc
11/10/202423h15GlobeNewswire Inc.MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLANNASDAQ:MGRXMangoceuticals Inc
03/10/202414h30GlobeNewswire Inc.MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsNASDAQ:MGRXMangoceuticals Inc
01/10/202419h05AllPennyStocks.comHealthcare Shares Rise Following Product Availability AnnouncementNASDAQ:MGRXMangoceuticals Inc
01/10/202413h30GlobeNewswire Inc.MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss TreatmentNASDAQ:MGRXMangoceuticals Inc
15/08/202415h25GlobeNewswire Inc.MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024NASDAQ:MGRXMangoceuticals Inc
13/08/202422h00GlobeNewswire Inc.MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology PatentNASDAQ:MGRXMangoceuticals Inc
09/08/202414h15GlobeNewswire Inc.MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and TirzepatideNASDAQ:MGRXMangoceuticals Inc
24/07/202414h15GlobeNewswire Inc.MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention TechnologyNASDAQ:MGRXMangoceuticals Inc
18/07/202422h05GlobeNewswire Inc.Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-AccessNASDAQ:MGRXMangoceuticals Inc
16/07/202414h20GlobeNewswire Inc.MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via SurescriptsNASDAQ:MGRXMangoceuticals Inc
12/07/202419h30GlobeNewswire Inc.MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentNASDAQ:MGRXMangoceuticals Inc
11/07/202414h15GlobeNewswire Inc.MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging MarketsNASDAQ:MGRXMangoceuticals Inc
18/06/202420h57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MGRXMangoceuticals Inc
06/06/202414h30GlobeNewswire Inc.MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyNASDAQ:MGRXMangoceuticals Inc
05/06/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MGRXMangoceuticals Inc
04/06/202422h00GlobeNewswire Inc.MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont TechnologiesNASDAQ:MGRXMangoceuticals Inc
04/06/202414h00GlobeNewswire Inc.MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone ImbalancesNASDAQ:MGRXMangoceuticals Inc
28/05/202414h30GlobeNewswire Inc.Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsNASDAQ:MGRXMangoceuticals Inc
23/05/202414h30GlobeNewswire Inc.MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsNASDAQ:MGRXMangoceuticals Inc
21/05/202414h30GlobeNewswire Inc.MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsNASDAQ:MGRXMangoceuticals Inc
16/05/202422h40GlobeNewswire Inc.MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationNASDAQ:MGRXMangoceuticals Inc
16/05/202419h59Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MGRXMangoceuticals Inc
16/05/202415h19Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MGRXMangoceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MGRX

Dernières Valeurs Consultées

COIN
SOLUSD
Solana
NASDAQ
AMZN
Amazon.com
EU
EN
Bouygues
EU
CS
Axa
NYSE
MCD
McDonalds
NYSE
NKE
Nike
EU
GLE
Societe Generale
EU
ML
Michelin
EU
SGO
Cie de SaintGobain
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
NASDAQ
GOOGL
Alphabet
EU
CAP
Capgemini
EU
AI
Air Liquide
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés